Mobia Medical
Mobia Medical is a publicly traded medical device company that develops and commercializes the Vivistim Paired VNS System, the first and only FDA-approved implantable neurostimulation therapy for chronic ischemic stroke survivors with moderate to severe upper extremity impairment, sold to US stroke centers and reimbursed via Medicare and commercial insurance.
- Company typePublic
- Founded2007
- HeadquartersAustin, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mobia Medical does
Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a publicly traded medical device company (Nasdaq: MOBI) headquartered in Austin, Texas with operations in Fridley, Minnesota and Newport Beach, California. Founded in 2007, the company develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that pairs targeted vagus nerve stimulation with functional rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe impairment. The platform is grounded in NIH-funded research by co-founder and Chief Scientific Officer Navzer Engineer (MD, PhD), published in Nature and The Lancet, and is protected by a portfolio of 25+ issued US patents with foreign counterparts.
The company monetizes Vivistim through hardware sales of the implantable neurostimulation system, supplemented by ongoing rehabilitation therapy delivery at US stroke centers and therapy sites. Pricing is reimbursement-driven via Medicare (with a positive Medicare payment change announced in November 2025) and commercial insurance with prior authorization; device pricing is not publicly disclosed. Revenue reached $32 million on a trailing-twelve-month basis (as of mid-2026), representing 105% year-over-year growth, although the company remains unprofitable as it scales. The go-to-market is enterprise field sales-led, with a dedicated US team of Territory Managers, Clinical Education Managers, Therapy Development Specialists, and Patient Engagement Managers supported by an inside sales function handling patient intake, prior authorizations, and appeals. A dedicated patient-facing website (vivistim.com) and an "Am I a Candidate?" pre-screening tool capture and qualify consumer demand.
Mobia maintains a portfolio of sub-brands including Vivistim, Vivistim Therapy, Paired VNS, and the adjacent Serenity brand for tinnitus neurostimulation. The company completed its Nasdaq IPO in May 2026, raising approximately $150 million in gross proceeds, and is led by President and CEO Richard Foust, a former Abbott and Guidant commercial leader, with board oversight from Chairman Dana G. Mead, Jr. and institutional investors including U.S. Venture Partners, Osage University Partners, Longitude Capital, and Action Potential Venture Capital.
Mobia Medical firmographics
Firmographics- Name
- Mobia Medical
- Legal name
- Mobia Medical, Inc.
- Website
- https://mobia.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Ipo
- Headcount range
- 101–250 employees
- Short description
- Mobia Medical is a publicly traded medical device company that develops and commercializes the Vivistim Paired VNS System, the first and only FDA-approved implantable neurostimulation therapy for chronic ischemic stroke survivors with moderate to severe upper extremity impairment, sold to US stroke centers and reimbursed via Medicare and commercial insurance.
- Ownership category
- akta.pro rank
Mobia Medical industry classification
Industry- Product category
- Neurostimulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Stroke & Vascular Neurology (HLAKAIAG)
Keywords
Where Mobia Medical is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Mobia Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
Revenue model
- Vivistim System Hardware Sales: Commercial-stage medical device revenue generated through sales of the FDA-approved Vivistim® Paired VNS™ implantable neurostimulator for chronic ischemic stroke rehabilitation. Reached $32 million in trailing-twelve-month revenue with 105% year-over-year growth. Revenue mix is one-time implantable device plus ongoing rehabilitation therapy delivery; covered by Medicare/insurance reimbursement (positive Medicare payment change announced November 2025).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Implantable medical device pricing, quote-based / not publicly disclosed |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Mobia Medical product offering
Product offeringCore offering
Mobia Medical develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. The company sells the device plus associated clinical support services to US stroke centers, therapy clinics, and implanting physicians, reimbursed primarily through Medicare and commercial insurance.
Product overview
Mobia Medical offers a single unified commercial-stage medical device franchise centered on the Vivistim® Paired VNS™ System and the associated Vivistim Therapy™ clinical protocol, both aimed at chronic ischemic stroke recovery. The implantable Vivistim System is supported by the Model 1001 vagus nerve lead as a hardware component. In parallel, the company maintains the Serenity® neurostimulation brand for the adjacent tinnitus indication. The current portfolio reflects Mobia Medical's evolution from MicroTransponder and the FDA approval of Vivistim as the first and only clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.
Differentiator
Problem solved
Functional benefit
Brands
- Vivistim: Vivistim® Paired VNS™ System and Vivistim Therapy™ — implantable neurostimulation system and related components for treatment of stroke survivors.
- Serenity
- Vivistim Therapy
- Paired VNS
Products and services
- Vivistim® Paired VNS™ System An FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. Sold to US stroke centers, hospitals, certified therapy clinics, and implanting physicians.
- Vivistim Therapy™ The clinical therapy protocol combining targeted vagus nerve stimulation delivered through the Vivistim System with structured functional exercises during rehabilitation to enable lasting improvements in motor pathways for chronic stroke recovery. Delivered at certified US stroke centers and therapy clinics.
Companies that use Mobia Medical
Customer profileSegments4 records
Ideal customer profiles3 records
Mobia Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Mobia Medical partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- American Heart Association Center for Health Technology & Innovation (Innovators' Network)coreMobia Medical joined the Innovators' Network of the American Heart Association's Center for Health Technology & Innovation and its American Stroke Association division (announced January 16, 2026). The affiliation reflects Mobia's commitment to advancing responsible, evidence-based innovation in cardiovascular and stroke care and supports broader dialogue around recovery standards and patient outcomes.
- MedTech InnovatorminorSelected as one of 61 startups for MedTech Innovator's 2023 global medtech accelerator cohort (June 2023), gaining access to mentorship, competitions, funding opportunities, and industry exposure.
Scale indicators13 records
Recent moves8 records
Expansion highlights6 records
Mobia Medical competitors and assessment
Company assessmentDirect peers
- Inspire Medical Systems: Inspire Medical Systems sells an implantable hypoglossal nerve stimulation system for obstructive sleep apnea, sharing Mobia's business model of an FDA-approved implantable neurostim device sold through a US specialty field-sales force to clinicians and reimbursed by Medicare and commercial payers.
- Axonics: Axonics (acquired by Boston Scientific in 2024) marketed rechargeable sacral neuromodulation implants for urinary and fecal dysfunction, an almost identical playbook to Vivistim — small implantable neurostim device, direct-to-specialist US field sales, and Medicare/commercial reimbursement dynamics in a chronic-condition population.
- LivaNova: LivaNova (formerly Cyberonics) commercializes the original implantable vagus nerve stimulation (VNS) therapy, historically for drug-resistant epilepsy and treatment-resistant depression; it is the closest direct mechanism competitor to Vivistim's paired VNS platform and provides a benchmark for VNS category economics.
- CVRx: CVRx sells the Barostim neo system, an implantable neuromodulation device for heart failure and resistant hypertension; it mirrors Mobia's playbook of an FDA-approved implantable neurostim treating a chronic-condition population via a US specialty sales force with Medicare-dependent economics.
- Nevro: Nevro markets the HFX 10 kHz spinal cord stimulation system for chronic pain, another implantable neuromodulation franchise commercialized through a US physician-specialist field force with payer-reimbursement-driven unit economics — directly comparable to Mobia's commercial motion.
Emerging players
- ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation (nVNS) via surface stimulation of the cervical vagus nerve for headache, epilepsy and other indications; it targets the same VNS mechanism as Vivistim but with a non-implantable delivery model, representing a potential adjacent or substitutive competitor for chronic neurological conditions.
Broad incumbents
- Medtronic: Medtronic operates the world's broadest neuromodulation portfolio (Activa DBS, InterStim sacral neuromodulation, Intellis SCS, Percept PC) and serves as a large-incumbent reference point for how a multi-indication neurostim franchise is commercialized and scaled; competes indirectly via its VNS-adjacent DBS and emerging neuro-recovery research programs.
- Abbott: Abbott's Neuromodulation business includes the Proclaim DRG and Infinity DBS systems, positioning it as a broad incumbent across multiple implantable neurostim indications; relevant to Mobia as a potential acquirer or competitor leveraging shared hospital call points and similar reimbursement infrastructure.
- Boston Scientific: Boston Scientific operates Vercise deep brain stimulation systems and acquired Axonics in 2024 to enter sacral neuromodulation, making it a broad incumbent in implantable neurostim with overlapping commercial channels and an active acquirer in the space (Mobia's leadership has multiple Boston Scientific alumni).
Others
- Penumbra: Penumbra is a neurovascular company whose stroke-thrombectomy franchise (and Lightning/Indigo product lines) is sold into the same US comprehensive stroke centers that are Mobia's Vivistim customers; it is not a direct competitor in chronic stroke recovery but shares the call point and is a relevant comp for stroke-care medtech economics.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Mobia Medical social profiles
Digital presenceMobia Medical compliance and trust
Trust signalCompliance6 records
Mobia Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mobia Medical leadership team
Management profileNumber of profiles
Profiles14 records
Mobia Medical funding detail
Funding detailFunding overview
Funding rounds13 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mobia Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mobia Medical
What does Mobia Medical do?
Mobia Medical develops and commercializes the Vivistim® Paired VNS™ System, an FDA-approved implantable neurostimulation device that delivers targeted vagus nerve stimulation paired with rehabilitation therapy to promote neuroplasticity and improve upper extremity motor function in chronic ischemic stroke survivors with moderate to severe arm impairment. The company sells the device plus associated clinical support services to US stroke centers, therapy clinics, and implanting physicians, reimbursed primarily through Medicare and commercial insurance.
Is Mobia Medical a public or private company?
Mobia Medical is a public company. It is classified as public and is currently ipo.
When was Mobia Medical founded?
Mobia Medical was founded in 2007. It employs 101 to 250 people.
Where is Mobia Medical based?
Mobia Medical is headquartered in Austin, United States, in the North America region.
How does Mobia Medical make money?
One revenue line is on record: vivistim System Hardware Sales.
Who are Mobia Medical's main competitors?
Direct peers on record are Inspire Medical Systems, Axonics, LivaNova, CVRx and Nevro. ElectroCore is listed as an emerging player. Broad incumbents are Medtronic, Abbott and Boston Scientific. Penumbra is listed as an others.
Does Mobia Medical have an API?
No public API is recorded for Mobia Medical.
What industry is Mobia Medical in?
Mobia Medical's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 334510 and its SIC code is 3845.